{"id":45421,"date":"2025-10-31T15:47:03","date_gmt":"2025-10-31T07:47:03","guid":{"rendered":"https:\/\/flcube.com\/?p=45421"},"modified":"2025-10-31T15:47:04","modified_gmt":"2025-10-31T07:47:04","slug":"eli-lilly-reports-54-yoy-revenue-surge-in-q3-2025-raises-full%e2%80%91year-guidance-to-63-b","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45421","title":{"rendered":"Eli Lilly Reports 54% YoY Revenue Surge in Q3\u202f2025, Raises Full\u2011Year Guidance to $63\u202fB"},"content":{"rendered":"\n<p><strong>Eli Lilly &amp; Co.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE: LLY<\/a>) today announced that its third\u2011quarter 2025 financial results exceeded expectations, posting a 54\u202f% year\u2011over\u2011year (YoY) revenue increase to <strong>$17.60\u202fbillion<\/strong>. The growth was driven primarily by volume gains in its flagship GLP\u20111\/GIP metabolic portfolio, including <strong>tirzepatide<\/strong> (Mounjaro\u00ae and Zepbound\u00ae).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-financial-highlights\"><strong>Key Financial Highlights<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Q3\u202f2025<\/th><th>YoY %<\/th><th>Q3\u202f2025 vs Q2\u202f2025<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Revenue<\/strong><\/td><td>$17.60\u202fB<\/td><td>+54\u202f%<\/td><td><\/td><\/tr><tr><td><strong>US Revenue<\/strong><\/td><td>$11.30\u202fB<\/td><td>+45\u202f%<\/td><td><\/td><\/tr><tr><td><strong>International Revenue<\/strong><\/td><td>$6.30\u202fB<\/td><td>+74\u202f%<\/td><td><\/td><\/tr><tr><td><strong>Mounjaro Revenue<\/strong><\/td><td>$6.52\u202fB<\/td><td>+109\u202f%<\/td><td><\/td><\/tr><tr><td><strong>Zepbound Revenue<\/strong><\/td><td>$3.59\u202fB<\/td><td>+185\u202f%<\/td><td><\/td><\/tr><tr><td><strong>Verzenio Revenue<\/strong><\/td><td>$1.47\u202fB<\/td><td>+7\u202f%<\/td><td><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>US Volume Growth<\/strong> \u2013 60\u202f% increase, offset by a 15\u202f% decline in realized prices.<\/li>\n\n\n\n<li><strong>International Volume Growth<\/strong> \u2013 66\u202f% increase; foreign\u2011exchange favorable by 6\u202f%.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\"><strong>Strategic Implications<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Metabolic Focus<\/strong> \u2013 Mounjaro and Zepbound continue to dominate sales momentum, reinforcing Lilly\u2019s leadership in type\u202f2 diabetes and obesity therapeutics.<\/li>\n\n\n\n<li><strong>Guidance Upgrade<\/strong> \u2013 The company now projects full\u2011year 2025 revenue of <strong>$63.0\u202fB \u2013 $63.5\u202fB<\/strong>, up from the $60.0\u202fB \u2013 $62.0\u202fB range previously set in Q2.<\/li>\n\n\n\n<li><strong>Pipeline Confidence<\/strong> \u2013 Strong commercial performance supports ongoing investment in Lilly\u2019s broader oncology and immunology pipelines.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/Lilly-reports-third-quarter-2025-financial-results-highlights-RD-pipeline-momentum-and-raises-2025-guidance.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of Lilly reports third-quarter 2025 financial results, highlights R&amp;D pipeline momentum and raises 2025 guidance.\"><\/object><a id=\"wp-block-file--media-99a91f87-f672-4149-92aa-996ce64236b3\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/Lilly-reports-third-quarter-2025-financial-results-highlights-RD-pipeline-momentum-and-raises-2025-guidance.pdf\">Lilly reports third-quarter 2025 financial results, highlights R&#038;D pipeline momentum and raises 2025 guidance<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/Lilly-reports-third-quarter-2025-financial-results-highlights-RD-pipeline-momentum-and-raises-2025-guidance.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-99a91f87-f672-4149-92aa-996ce64236b3\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly &amp; Co. (NYSE: LLY) today announced that its third\u2011quarter 2025 financial results exceeded&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45422,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[199,27,911],"class_list":["post-45421","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-eli-lilly","tag-finanical-reports","tag-nyse-lly"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eli Lilly Reports 54% YoY Revenue Surge in Q3\u202f2025, Raises Full\u2011Year Guidance to $63\u202fB - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eli Lilly &amp; Co. (NYSE: LLY) today announced that its third\u2011quarter 2025 financial results exceeded expectations, posting a 54\u202f% year\u2011over\u2011year (YoY) revenue increase to $17.60\u202fbillion. The growth was driven primarily by volume gains in its flagship GLP\u20111\/GIP metabolic portfolio, including tirzepatide (Mounjaro\u00ae and Zepbound\u00ae).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45421\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly Reports 54% YoY Revenue Surge in Q3\u202f2025, Raises Full\u2011Year Guidance to $63\u202fB\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly &amp; Co. (NYSE: LLY) today announced that its third\u2011quarter 2025 financial results exceeded expectations, posting a 54\u202f% year\u2011over\u2011year (YoY) revenue increase to $17.60\u202fbillion. The growth was driven primarily by volume gains in its flagship GLP\u20111\/GIP metabolic portfolio, including tirzepatide (Mounjaro\u00ae and Zepbound\u00ae).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45421\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-31T07:47:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-31T07:47:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3110.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45421#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45421\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly Reports 54% YoY Revenue Surge in Q3\u202f2025, Raises Full\u2011Year Guidance to $63\u202fB\",\"datePublished\":\"2025-10-31T07:47:03+00:00\",\"dateModified\":\"2025-10-31T07:47:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45421\"},\"wordCount\":203,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45421#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3110.webp\",\"keywords\":[\"Eli Lilly\",\"Finanical Reports\",\"NYSE: LLY\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45421#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45421\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45421\",\"name\":\"Eli Lilly Reports 54% YoY Revenue Surge in Q3\u202f2025, Raises Full\u2011Year Guidance to $63\u202fB - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45421#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45421#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3110.webp\",\"datePublished\":\"2025-10-31T07:47:03+00:00\",\"dateModified\":\"2025-10-31T07:47:04+00:00\",\"description\":\"Eli Lilly & Co. (NYSE: LLY) today announced that its third\u2011quarter 2025 financial results exceeded expectations, posting a 54\u202f% year\u2011over\u2011year (YoY) revenue increase to $17.60\u202fbillion. The growth was driven primarily by volume gains in its flagship GLP\u20111\\\/GIP metabolic portfolio, including tirzepatide (Mounjaro\u00ae and Zepbound\u00ae).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45421#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45421\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45421#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3110.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3110.webp\",\"width\":1080,\"height\":608,\"caption\":\"Eli\u202fLilly Reports 54% YoY Revenue Surge in Q3\u202f2025, Raises Full\u2011Year Guidance to $63\u202fB\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45421#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly Reports 54% YoY Revenue Surge in Q3\u202f2025, Raises Full\u2011Year Guidance to $63\u202fB\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly Reports 54% YoY Revenue Surge in Q3\u202f2025, Raises Full\u2011Year Guidance to $63\u202fB - Insight, China&#039;s Pharmaceutical Industry","description":"Eli Lilly & Co. (NYSE: LLY) today announced that its third\u2011quarter 2025 financial results exceeded expectations, posting a 54\u202f% year\u2011over\u2011year (YoY) revenue increase to $17.60\u202fbillion. The growth was driven primarily by volume gains in its flagship GLP\u20111\/GIP metabolic portfolio, including tirzepatide (Mounjaro\u00ae and Zepbound\u00ae).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45421","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly Reports 54% YoY Revenue Surge in Q3\u202f2025, Raises Full\u2011Year Guidance to $63\u202fB","og_description":"Eli Lilly & Co. (NYSE: LLY) today announced that its third\u2011quarter 2025 financial results exceeded expectations, posting a 54\u202f% year\u2011over\u2011year (YoY) revenue increase to $17.60\u202fbillion. The growth was driven primarily by volume gains in its flagship GLP\u20111\/GIP metabolic portfolio, including tirzepatide (Mounjaro\u00ae and Zepbound\u00ae).","og_url":"https:\/\/flcube.com\/?p=45421","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-31T07:47:03+00:00","article_modified_time":"2025-10-31T07:47:04+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3110.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45421#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45421"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly Reports 54% YoY Revenue Surge in Q3\u202f2025, Raises Full\u2011Year Guidance to $63\u202fB","datePublished":"2025-10-31T07:47:03+00:00","dateModified":"2025-10-31T07:47:04+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45421"},"wordCount":203,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45421#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3110.webp","keywords":["Eli Lilly","Finanical Reports","NYSE: LLY"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45421#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45421","url":"https:\/\/flcube.com\/?p=45421","name":"Eli Lilly Reports 54% YoY Revenue Surge in Q3\u202f2025, Raises Full\u2011Year Guidance to $63\u202fB - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45421#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45421#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3110.webp","datePublished":"2025-10-31T07:47:03+00:00","dateModified":"2025-10-31T07:47:04+00:00","description":"Eli Lilly & Co. (NYSE: LLY) today announced that its third\u2011quarter 2025 financial results exceeded expectations, posting a 54\u202f% year\u2011over\u2011year (YoY) revenue increase to $17.60\u202fbillion. The growth was driven primarily by volume gains in its flagship GLP\u20111\/GIP metabolic portfolio, including tirzepatide (Mounjaro\u00ae and Zepbound\u00ae).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45421#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45421"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45421#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3110.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3110.webp","width":1080,"height":608,"caption":"Eli\u202fLilly Reports 54% YoY Revenue Surge in Q3\u202f2025, Raises Full\u2011Year Guidance to $63\u202fB"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45421#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly Reports 54% YoY Revenue Surge in Q3\u202f2025, Raises Full\u2011Year Guidance to $63\u202fB"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3110.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45421","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45421"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45421\/revisions"}],"predecessor-version":[{"id":45424,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45421\/revisions\/45424"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45422"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45421"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45421"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45421"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}